Akathisia

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Retrieved on: 
Friday, December 22, 2023
Neurology, Biotechnology, Pharmaceutical, General Health, Health, FDA, Mental Health, Clinical Trials, Akathisia, BMY, Conference, Cognition, Food, Bristol Myers Squibb, Simpson Thacher & Bartlett, Treatment, Drug development, Extrapyramidal symptoms, PRTC, Psychiatry, Bipolar I disorder, Acquisition, PDUFA, Psychosis, Conference call, NDA, KRTX, Prolactin, Citigroup, Therapy, Covington & Burling, M1, Goldman Sachs, Weight gain, Growth, Webcast, Patient, Safety, M4, Pharmaceutical industry

The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • ET
    PRINCETON, N.J. & BOSTON -- Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Retrieved on: 
Friday, December 22, 2023
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Akathisia, BMY, Cognition, Food, Bristol Myers Squibb, Simpson Thacher & Bartlett, Drug development, Extrapyramidal symptoms, Psychiatry, Bipolar I disorder, FDA, Acquisition, PDUFA, Psychosis, NDA, KRTX, Prolactin, Citigroup, Therapy, Schizophrenia, Covington & Burling, M1, Goldman Sachs, Weight gain, Growth, Webcast, Patient, Safety, M4, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Retrieved on: 
Friday, December 22, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Akathisia, BMY, Cognition, Food, Bristol Myers Squibb, Simpson Thacher & Bartlett, Multimedia, Drug development, Extrapyramidal symptoms, Psychiatry, Bipolar I disorder, FDA, Acquisition, PDUFA, Psychosis, NDA, KRTX, Prolactin, Citigroup, Therapy, Schizophrenia, Covington & Burling, M1, Goldman Sachs, Weight gain, Growth, Webcast, Patient, Safety, M4, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
Monday, November 6, 2023
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Behavioral neuroscience, Attention, Headache, Incidence, CMAI, Food, Mini–Mental State Examination, DSM-IV codes, Brexpiprazole, OPDC, MD, Psychiatry, Food and Drug Administration Amendments Act of 2007, Deficit spending, Verbal aggression, Dementia, Multimedia, Medicine, Interview, Pneumonia, Somnolence, Lundbeck, Locomotion, Commercialization, JAMA Neurology, Cachexia, Screaming, Caregiver, Passive-aggressive behavior, Aggression, Saint Louis University School of Medicine, MMSE, Heart, Ōtsuka, Akathisia, Contra body movement, Agitation, Medication, Tearing, Anxiety, IPA, Patient, Diagnosis, Disease, Restless, Pharmaceutical industry, Nursing, Birth control

REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.

Key Points: 
  • REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.
  • Participants also required a diagnosis that met The International Psychogeriatric Association’s (IPA) provisional definition of agitation in patients with cognitive impairment or dementia.
  • “Agitation associated with dementia due to Alzheimer’s disease can be very challenging and emotionally distressing for patients and family members caring for them.
  • The trial had high rates of patients completing the trial: 86.8% of the brexpiprazole group and 88.9% of the placebo group.

Antidepressants can cause withdrawal symptoms – here’s what you need to know

Retrieved on: 
Thursday, June 22, 2023
People, Seizure, Learning, Lightheadedness, Plasma protein binding, Royal college, Headache, Depression, Nicotine, Benzodiazepine, Akathisia, Anxiety, Sleep, National Institute, Anger, Head, Brain, Caffeine, Sensation, Grammatical mood, Tablet, Insomnia, Dizziness, Patient, Time, Risk, Serotonin, Nervous system, Menopause, Nausea, Panorama (British TV programme), Memory, Irritability, Panic, Cramp, Dietary supplement, Life insurance, Drug, Medical imaging, Residential care, Birth control, Pharmaceutical industry

Millions of people worldwide take antidepressants to help with depression. But as a recent BBC Panorama found, many aren’t aware of the fact that antidepressants can cause withdrawal symptoms when you stop taking them. For some, these symptoms can be severe and long-lasting. Here’s what you should know.What causes antidepressant withdrawal?This process of adaption is often termed physical dependence, which leads to tolerance (lessening effects over time) and withdrawal when stopping.

Key Points: 


Millions of people worldwide take antidepressants to help with depression. But as a recent BBC Panorama found, many aren’t aware of the fact that antidepressants can cause withdrawal symptoms when you stop taking them. For some, these symptoms can be severe and long-lasting. Here’s what you should know.

What causes antidepressant withdrawal?

    • This process of adaption is often termed physical dependence, which leads to tolerance (lessening effects over time) and withdrawal when stopping.
    • After even just a few weeks of antidepressant use, our serotonin receptors become less sensitive, meaning that we probably need more serotonin to elicit the same effects.
    • This is what causes withdrawal symptoms.

What are the symptoms?

    • Emotional withdrawal symptoms include low mood, anxiety, panic attacks, irritability, anger, crying spells and feeling suicidal.
    • There are a few ways to distinguish withdrawal symptoms from relapse – the return of a past mental health condition.
    • Physical withdrawal symptoms will be distinct from the original condition, and sometimes the emotional symptoms are recognisably different from the symptoms you initially had.

How long do withdrawal symptoms last?

    • Many people (including practitioners) believe withdrawal symptoms only last as long as it takes the drug to leave your system – typically, days or weeks.
    • Clinical studies have also shown that antidepressant withdrawal symptoms can last for weeks, months and, in some people, years.

Does withdrawal only happen with long-term use?

    • One patient survey found only a small minority experienced withdrawal after taking the drug for a few months.
    • But more than half who’d taken antidepressants longer than three years experienced withdrawal – of which, half reported moderate or severe symptoms.

How should you stop antidepressants?

    • While some patients can tolerate this, we know that for many long-term antidepressant users, this approach produces intolerable withdrawal symptoms that can make it impossible to stop these drugs.
    • The last few milligrams of these drugs are the hardest to come off, so need to be reduced particularly carefully.
    • But it’s important people are made aware of the risk of withdrawal effects, so they can make an informed decision.

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology

Retrieved on: 
Friday, May 19, 2023
Huntington's disease, Neuron, VMAT2, KINECT, Akathisia, Somnolence, Week, Disease, McGovern Medical School, New Drug Application, Heredity, Neurocrine Biosciences, Brain, Department of Neurology, Xuanwu hospital, Fatigue, HSG, DSM-IV codes, Shanda, TMC, Suicide, Patient, Manuscript, SAN, Memorial Hermann Health System, Chorea, Quality of life, PDUFA, Neurology, Suicidal ideation, FDA, Lancet, The Lancet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Propane, Medical imaging, HD, Valbenazine

SAN DIEGO, May 19, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that the complete study results from its Phase 3 KINECT™-HD study investigating valbenazine for the treatment of chorea associated with Huntington's disease (HD) has been published in The Lancet Neurology online edition and will appear in the June 2023 print issue. The study met pre-defined primary and secondary endpoints of improvement in chorea severity and global impression of change, demonstrating a reduction in chorea symptoms associated with HD and improvement of overall chorea severity as noticed by clinicians and patients, with improvement seen as early as Week 2 of the initial dose in the 12-week study.

Key Points: 
  • "The KINECT-HD study data demonstrated statistically significant improvement in chorea associated with HD as compared with placebo.
  • The safety profile for participants with chorea associated with HD was consistent with the known safety profile of valbenazine.
  • The KINECT-HD study marked the first-ever implementation of the Huntington's Disease Health Index (HD-HI) in a Phase 3 trial.
  • The filing included data from the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label study of valbenazine in adults with chorea associated with HD.

Global Psychiatry Partnering Deal Trends, Players and Financials Directory/Report 2016-2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Mental Health, Tardive dyskinesia, Chapter Five, A-Z, Chapter Six, Chronic fatigue syndrome, Bulimia nervosa, Tourette syndrome, Chapter Two, Research, Sleep disorder, Alzheimer's disease, Vascular dementia, Personality disorder, Confidentiality, Learning disability, Sleep apnea, Anxiety disorder, Three-body problem, Eating disorder, Cognitive deficit, Psychiatry, Chapter One, Panic disorder, Obsessive–compulsive disorder, Hyperlink, Intellectual property, Collection, Attention deficit hyperactivity disorder, Chapter Four, Chapter Three, Bipolar disorder, Narcolepsy, Directory, Pharmaceutical industry, Lease, Risk management, Commercial property, Property management, Anorexia nervosa, Dystonia, Akathisia, Autism spectrum, Dementia, Insomnia, Depression, Schizophrenia, Delirium

The "Global Psychiatry Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Psychiatry Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The report takes readers through the comprehensive psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering psychiatry deals.
  • Chapter 6 provides a comprehensive directory of all psychiatry partnering deals by specific psychiatry target announced since 2016.
  • In addition, a comprehensive appendix is provided with each report of all psychiatry partnering deals signed and announced since 2016.

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio

Retrieved on: 
Wednesday, February 22, 2023
Patent, Science, Dark Enlightenment, PTSD, Akathisia, NMDA, Patient, 1836 U.S. Patent Office fire, Depression, Food, Suicide, Cyclothymia, MDD, Orange Book, FDA, DSM-IV codes, SSRI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

RADNOR, Pa., Feb. 22, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") has issued U.S. Patent No.

Key Points: 
  • RADNOR, Pa., Feb. 22, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") has issued U.S. Patent No.
  • The licensed patents cover certain pharmaceutical formulations and their uses in treating a variety of neuropsychiatric conditions, including bipolar depression, major depressive disorder, PTSD, and suicidality.
  • "The grant of this new patent augments the strength of NRx Pharmaceuticals' intellectual property, which consists of about 90 patents and patent applications globally," said Stephen Willard, Chief Executive Officer of NRx Pharmaceuticals.
  • In 2023, the company expects to have additional patents granted from its pending portfolio and to file more patent applications in the U.S. and internationally.

Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression

Retrieved on: 
Tuesday, February 21, 2023
Extrapyramidal symptoms, Lurasidone, Somnolence, Serotonin, Intas Pharmaceuticals, Akathisia, Thought, Safety, Dopamine, Agitation, Schizophrenia, Behavior, Food, Accord, Anxiety, FDA, DSM-IV codes, Nausea, Market portfolio, US Foods, Tablet, Mental health, Pharmaceutical industry

DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs.

Key Points: 
  • DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs.
  • Lurasidone is an oral, atypical antipsychotic, which is a first-line treatment option for the management of schizophrenia in adults and adolescents.
  • "A generic option in mental health treatment provides more accessible healthcare to those who are in need."
  • Adverse reactions 2 of lurasidone for treatment of schizophrenia and bipolar depression include somnolence, akathisia, which is a feeling of restlessness, anxiety, and/or agitation, and extrapyramidal symptoms.

Gedeon Richter: The incidence of side effects decreased over time with cariprazine

Retrieved on: 
Tuesday, October 18, 2022
Akathisia, Time, Birth, Female, ECNP, Woman, Schizophrenia, European College of Neuropsychopharmacology, Patient, Gedeon Richter, Industry, Polypharmacy, Cariprazine, Lists of diseases, Incidence, Product, Clinical trial, Scott Richter, Pharmaceutical industry

Issues regarding polypharmacy, and the special needs of women with schizophrenia were also highlighted in an industry-sponsored product theater and satellite symposium.

Key Points: 
  • Issues regarding polypharmacy, and the special needs of women with schizophrenia were also highlighted in an industry-sponsored product theater and satellite symposium.
  • One of the poster presentations at ECNP authored by Professor Christoph U. Correll highlighted that the incidence of adverse drug reactions with cariprazine decreases over time.
  • Furthermore, higher doses of cariprazine do not seem to increase neither rescue medication use nor extrapyramidal-related symptoms such as akathisia.
  • Compared to previous treatment, patients with schizophrenia needed less rescue medications with cariprazine and experienced fewer side effects.